ARGX ArGEN-X SE

argenx Appoints Steve Krognes to Board of Directors

argenx Appoints Steve Krognes to Board of Directors



February 27, 2023

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Steve Krognes was appointed as a non-executive director to its Board of Directors. He will also become the chairperson of the Audit and Compliance Committee.

As a result of the appointment of Mr. Krognes, Werner Lanthaler has formally resigned as non-executive director of the Board of Directors and chairperson of the Audit and Compliance Committee to enable this important step in long-term succession planning.

“We welcome Steve to the Board and are confident that with his strong financial and compliance expertise and valuable industry knowledge, he possesses the ideal profile to support argenx on our innovative, entrepreneurial mission,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “I would also like to express my gratitude to Werner for his substantial contributions over the last eight years. His entrepreneurial spirit combined with his broad experience in finance and executive leadership within biopharma has helped guide us from a research and development company to a fully integrated, global immunology company.”

The voting result and all documents relating to the shareholders’ meeting will be available on the argenx website at .

About argenx 

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan. For more information, visit and follow us on , , and . 

For further information, please contact:  

Media:

Erin Murphy

Investors:

Beth DelGiacco



EN
27/02/2023

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Mathijs Geerts Danau
  • Wim Hoste
  • Wim Lewi
BEKB BEKAERT SA
EURN EURONAV NV ... (+11)

Morning Notes : ARGX BB, BEKB BB, CRBN NA, CMBT BB, SEQUA BB, SOF BB, ...

: ARGX BB, BEKB BB, CRBN NA, CMBT BB, SEQUA BB, SOF BB, UCB BB, SHUR BB, CTPNV NA, DEME BB, SYENS BB

BEKB BEKAERT SA
EURN EURONAV NV
UCB UCB S.A.
SOF SOFINA SA
CSM CORBION NV
ARGX ARGEN-X SE
SEQUA SEQUANA MEDICAL
CTPNV CTP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
SYENS SYENSQO
4h / 1m 4h / 1m 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx FY25 results come with positive phase 3 ocular MG readout

argenx reported $4.2b (CSS: $ 4.13b) in FY25 global product net sales and operating income of $ 1.1b marking 2025 argenx first year of operating profitability. A major update is the positive ocular MG readout that will expand the MG patient population with 7K patients. This year we look forward to the myositis readout in 3Q26 and the empasiprubart readout in MMN in 4Q26. We reiterate our € 900 TP and BUY rating.

4h / 17m 4h / 17m 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Reports Full Year 2025 Financial Results and Provides Fourth Qu...

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update $1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative (“seronegative”) gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET ...

5h / 59m 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Tr...

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis Study met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information  February 26, 2026, 6:30 AM CET    Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company co...

6h / 29m 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx to Present at TD Cowen 46th Annual Healthcare Conference

argenx to Present at TD Cowen 46th Annual Healthcare Conference February 23, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Operating Officer, will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2 at 11:50 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at . A replay of the webcast will be available on the arg...

February 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch